In this article, we delve into the positive effects of intermittent hypoxia and explore the underlying mechanisms driving these benefits.
This year, Ai Mediq had the privilege of participating in the European Society of Cardiology (ESC) Congress held in the city of Amsterdam. This prestigious congress brings together experts from private and public institutions worldwide to exchange knowledge and discoveries in the realm of cardiovascular medicine.
This week we were happy to join our friends and colleagues at the European cardiological society congress in Barcelona.
Last Friday (26th of July 2019) one of the most recent clinical trials involving ReOxy has been registered with CliniclTrials.gov database with NCT04034082 identifier.
Ai Mediq is pleased to announce approval of new clinical trial named “Evaluation of clinical efficacy of interval hypoxic-hyperoxic trainings in treatment of patients with reduced ejection fraction of left ventricle (2-3 NYHA)